Vincerx 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
enitociclib (VIP152) / Vincerx
NCT05371054: Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Active, not recruiting
1/2
8
US
Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, Venclexta, Venclyxto, VIP152, Enitociclib, Prednisone, Rayos, Deltasone, Prednisone Intensol, PET, Positron emission imaging, EKG, Electrocardiogram, ECHO, Echocardiogram, CT neck chest, abdomen, and pelvis, Computed tomography neck chest, abdomen, and pelvis, MRI, Magnetic resonance imaging, Bone marrow aspiration/Biopsy, BM aspiration/Bx
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
07/24
12/25
VNC-152-101, NCT02635672: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Completed
1
110
Europe, US, RoW
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, pembrolizumab, VIP152 (BAY 1251152) 15 mg
Vincerx Pharma, Inc.
Neoplasms
11/24
11/24
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
VIP943 / Vincerx
VNC-943-101, NCT06034275: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Jul 2022 - Dec 2023: Topline data from trial solid tumors
Recruiting
1
36
US
VIP943 (QW), VIP943 (BIW)
Vincerx Pharma, Inc.
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
05/25
12/25
VIP236 / Vincerx
NCT05712889: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Completed
1
29
US, RoW
VIP236 (Q3W), VIP236 (Q2W)
Vincerx Pharma, Inc.
Neoplasms
10/24
10/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
enitociclib (VIP152) / Vincerx
NCT05371054: Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Active, not recruiting
1/2
8
US
Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, Venclexta, Venclyxto, VIP152, Enitociclib, Prednisone, Rayos, Deltasone, Prednisone Intensol, PET, Positron emission imaging, EKG, Electrocardiogram, ECHO, Echocardiogram, CT neck chest, abdomen, and pelvis, Computed tomography neck chest, abdomen, and pelvis, MRI, Magnetic resonance imaging, Bone marrow aspiration/Biopsy, BM aspiration/Bx
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
07/24
12/25
VNC-152-101, NCT02635672: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Completed
1
110
Europe, US, RoW
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, pembrolizumab, VIP152 (BAY 1251152) 15 mg
Vincerx Pharma, Inc.
Neoplasms
11/24
11/24
VNC-152-102, NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Terminated
1
6
Europe, US
VIP152, BTKi
Vincerx Pharma, Inc.
Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Richter Syndrome, MYC Amplification, MYC Overexpression, MYC Translocation
05/23
05/23
VIP943 / Vincerx
VNC-943-101, NCT06034275: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Jul 2022 - Dec 2023: Topline data from trial solid tumors
Recruiting
1
36
US
VIP943 (QW), VIP943 (BIW)
Vincerx Pharma, Inc.
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
05/25
12/25
VIP236 / Vincerx
NCT05712889: Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

Completed
1
29
US, RoW
VIP236 (Q3W), VIP236 (Q2W)
Vincerx Pharma, Inc.
Neoplasms
10/24
10/24

Download Options